EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1

AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for HCV genotype 1.METHOD : The study population was 253 patients who were enrolled in the Akita hepatitis C study group from 2015 to 2016. We followed them until 24 weeks after the end of treatment.RESULT : The sustained virological response (SVR) at 24 weeks after the end of treatment rates were 84.2%. In univariate analyses, the Y93 mutation and a history of triple therapy with protease inhibitor reduced the SVR 24 rate. In multivariate analyses, the Y93H mutation, a history of triple therapy with protease inhibitor, and LC status reduced the SVR 24 rate. The most frequently reported adverse event was ALT elevation, noted in 25.7% of patients. 10.7% of patients had T-Bil elevation, 7.1% experienced drug rush, 11.5% experienced respiratory symptoms, 10.3% developed a fever, and 7.1% experienced digestive symptom. Only 9 (3.6%) patients stopped taking the drugs due to drug-related severe adverse events.CONCLUSION : DCV and ASV therapy showed a high efficacy and low rate of adverse events